Allogene Therapeutics, Inc. (NASDAQ:ALLO) Position Increased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 116.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,498 shares of the company’s stock after purchasing an additional 17,471 shares during the period. Daiwa Securities Group Inc.’s holdings in Allogene Therapeutics were worth $104,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vontobel Holding Ltd. increased its stake in Allogene Therapeutics by 28.6% during the fourth quarter. Vontobel Holding Ltd. now owns 18,000 shares of the company’s stock valued at $58,000 after purchasing an additional 4,000 shares during the last quarter. Principal Financial Group Inc. increased its stake in Allogene Therapeutics by 1.7% during the third quarter. Principal Financial Group Inc. now owns 266,154 shares of the company’s stock valued at $844,000 after purchasing an additional 4,531 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Allogene Therapeutics by 7.3% during the fourth quarter. Harbor Capital Advisors Inc. now owns 73,510 shares of the company’s stock valued at $236,000 after purchasing an additional 4,991 shares during the last quarter. Arizona State Retirement System increased its stake in Allogene Therapeutics by 22.2% during the fourth quarter. Arizona State Retirement System now owns 30,458 shares of the company’s stock valued at $98,000 after purchasing an additional 5,543 shares during the last quarter. Finally, Swiss National Bank increased its stake in Allogene Therapeutics by 3.0% during the third quarter. Swiss National Bank now owns 192,400 shares of the company’s stock valued at $610,000 after purchasing an additional 5,600 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Up 1.2 %

ALLO stock opened at $2.89 on Friday. The company has a market capitalization of $493.38 million, a P/E ratio of -1.38 and a beta of 0.81. The company has a 50-day simple moving average of $4.32 and a 200 day simple moving average of $3.54. Allogene Therapeutics, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $6.89.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.04. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative return on equity of 53.76%. Equities analysts anticipate that Allogene Therapeutics, Inc. will post -1.69 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ALLO shares. JPMorgan Chase & Co. lowered their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 27th. JMP Securities restated a “market perform” rating on shares of Allogene Therapeutics in a research report on Friday, January 5th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Tuesday, March 19th. Guggenheim lowered shares of Allogene Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, January 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $12.94.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).